HK Stock Market Move | IMMUNEONCO-B(01541) is up over 4% recently with multiple clinical research advancements announced. Clinical study IMM0306 is actively recruiting and observing participants.

IMMUNEONCO-B (01541) is now up more than 4%, as of the time of writing, it is up 4.65% at HK$7.65, with a turnover of HK$34.7809 million. In terms of news, Immuneonco announced that the phase Ib/IIa clinical trial of IMM0306 in combination with lenalidomide for the treatment of chronic lymphocytic leukemia has recruited 27 evaluable patients as of October 26. As of October 26, the overall response rate (ORR) and complete response rate (CRR) in 25 evaluable patients with R/R FL were 84% and 40% respectively, while the overall response rate in R/R MZL in two evaluable patients reached 100%, indicating a prominent efficacy signal. The study is currently actively recruiting and observing. It is worth noting that Immuneonco's core product IMM01 (venetoclax) combined with azacitidine for the first-line treatment of chronic myelomonocytic leukemia (CMML) has successfully completed dosing in the first patient in the phase III clinical trial. In addition, the company has initiated a phase II clinical trial of IMM27M for the treatment of estrogen receptor-positive (ER+) advanced breast cancer after endocrine therapy failure or recurrence, and has recruited the first patient.